Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with ...

Living with IPF has brought many emotional ups and downs for columnist Sam Kirton, and recent events have caused him to hit ...